Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 10.08B P/E 32.01 EPS this Y - Ern Qtrly Grth -63.00%
Income 203.2M Forward P/E - EPS next Y - 50D Avg Chg -2.00%
Sales 2.07B PEG - EPS past 5Y - 200D Avg Chg -14.00%
Dividend 1.00% Price/Book 5.11 EPS next 5Y - 52W High Chg -27.00%
Recommedations - Quick Ratio - Shares Outstanding 89.44M 52W Low Chg 13.00%
Insider Own - ROA - Shares Float 36.69M Beta 0.98
Inst Own - ROE - Shares Shorted/Prior -/- Price 111.71
Gross Margin 55.11% Profit Margin 9.83% Avg. Volume 2,880 Target Price -
Oper. Margin 10.14% Earnings Date Dec 10 Volume 786 Change -1.54%
About CARL ZEISS MEDITEC AG UNSP ADR

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

CARL ZEISS MEDITEC AG UNSP ADR News
11/12/24 German company Zeiss opens global capability centre in India
11/01/24 Carl Zeiss Meditec (ETR:AFX) Will Be Hoping To Turn Its Returns On Capital Around
10/14/24 Is Carl Zeiss Meditec AG's (ETR:AFX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
10/09/24 ZEISS expands ophthalmic offerings to improve patient care with new digital AI tools and revolutionary surgical solutions
09/30/24 ZEISS introduces its latest Robotic Visualisation System for neuro surgery
09/30/24 What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
09/26/24 ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
09/12/24 ZEISS Redefines Disease Management and Treatment within the ZEISS Retina Workflow
09/02/24 The three-year loss for Carl Zeiss Meditec (ETR:AFX) shareholders likely driven by its shrinking earnings
08/29/24 ZEISS innovation paves way to more personalized patient care with cutting-edge AI technology and industry-leading surgical solutions
08/07/24 Private companies account for 59% of Carl Zeiss Meditec AG's (ETR:AFX) ownership, while institutions account for 22%
02:51 AM An Intrinsic Calculation For Carl Zeiss Meditec AG (ETR:AFX) Suggests It's 37% Undervalued
05/30/24 ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care
05/25/24 Returns At Carl Zeiss Meditec (ETR:AFX) Appear To Be Weighed Down
05/11/24 Carl Zeiss Meditec Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/06/24 Declining Stock and Solid Fundamentals: Is The Market Wrong About Carl Zeiss Meditec AG (ETR:AFX)?
04/22/24 What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
04/04/24 Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
03/28/24 ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024
03/25/24 Carl Zeiss Meditec's (ETR:AFX) investors will be pleased with their respectable 63% return over the last five years